Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae: Analysis of cases and evaluation of in vitro activity of fosfomycin-containing combinations
•Clinical characteristics and fosfomycin synergism of KPC-variants were investigated.•KPC-variant detection follows a previous CZA-susceptible KPC-Kp in the same patient.•Treatment with meropenem achieved clinical cure in all the patients.•Fosfomycin plus meropenem resulted in full synergism in 40%...
Saved in:
| Published in | Journal of Global Antimicrobial Resistance Vol. 33; pp. 321 - 327 |
|---|---|
| Main Authors | , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier Ltd
01.06.2023
Elsevier |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | •Clinical characteristics and fosfomycin synergism of KPC-variants were investigated.•KPC-variant detection follows a previous CZA-susceptible KPC-Kp in the same patient.•Treatment with meropenem achieved clinical cure in all the patients.•Fosfomycin plus meropenem resulted in full synergism in 40% of cases.•FOS plus MEM may be an option for KPC-variant infections at low risk of mortality.
Little is known regarding outcomes and optimal therapeutic regimens of infections caused by Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) resistant to ceftazidime/avibactam (CZA) and susceptible to meropenem (MEM). Although susceptible to MEM in vitro, the possibility of developing MEM resistance overtime is a concern. We describe the clinical characteristics of patients with colonization/infection due to KPC variants with a focus on the in vitro activity of fosfomycin (FOS)-containing combinations.
Patients with colonization/infection due to a KPC variant were included. Fosfomycin susceptibility was performed by agar dilution method. Synergistic activity of FOS-based combinations was evaluated by gradient strip-agar diffusion method. The emergence of in vitro MEM resistance was also tested.
Eleven patients were included: eight with infection [four with ventilator-associated pneumonia and four with bloodstream infections] and three with colonization. Previous therapy with CZA was administered to all patients (with a mean cumulative duration of 23 days). All subjects with infection received meropenem, in monotherapy (n = 4) or with amikacin (n = 2) or fosfomycin (n = 2), and achieved clinical cure. A new CZA-susceptible and MEM-resistant KPC-Kp strain was subsequently isolated in three patients (27.3%). Meropenem/vaborbactam (MVB) showed high in vitro activity, while FOS+MEM combination was synergistic in 40% of cases. In vitro resistance to MEM was observed with maintenance of CZA resistance.
Detection of KPC variants may occur within the same patient, especially if CZA has been previously administered. Although clinical success has been obtained with carbapenems, the emergence of MEM resistance is a concern. Fosfomycin plus meropenem is synergistic and may be a valuable combination option for KPC variants, while MVB may be considered in monotherapy. The detection of KPC variants in an endemic setting for KPC-Kp represents a worryingly emerging condition. The optimal therapeutic approach is still unknown and the development of meropenem resistance is of concern, which may lead to therapeutic failure in clinical practice. In these cases, the addition of fosfomycin to meropenem, or a more potent antibiotic, such as meropenem/vaborbactam, may be valuable therapeutic options. |
|---|---|
| AbstractList | Little is known regarding outcomes and optimal therapeutic regimens of infections caused by Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) resistant to ceftazidime/avibactam (CZA) and susceptible to meropenem (MEM). Although susceptible to MEM in vitro, the possibility of developing MEM resistance overtime is a concern. We describe the clinical characteristics of patients with colonization/infection due to KPC variants with a focus on the in vitro activity of fosfomycin (FOS)-containing combinations.
Patients with colonization/infection due to a KPC variant were included. Fosfomycin susceptibility was performed by agar dilution method. Synergistic activity of FOS-based combinations was evaluated by gradient strip-agar diffusion method. The emergence of in vitro MEM resistance was also tested.
Eleven patients were included: eight with infection [four with ventilator-associated pneumonia and four with bloodstream infections] and three with colonization. Previous therapy with CZA was administered to all patients (with a mean cumulative duration of 23 days). All subjects with infection received meropenem, in monotherapy (n = 4) or with amikacin (n = 2) or fosfomycin (n = 2), and achieved clinical cure. A new CZA-susceptible and MEM-resistant KPC-Kp strain was subsequently isolated in three patients (27.3%). Meropenem/vaborbactam (MVB) showed high in vitro activity, while FOS+MEM combination was synergistic in 40% of cases. In vitro resistance to MEM was observed with maintenance of CZA resistance.
Detection of KPC variants may occur within the same patient, especially if CZA has been previously administered. Although clinical success has been obtained with carbapenems, the emergence of MEM resistance is a concern. Fosfomycin plus meropenem is synergistic and may be a valuable combination option for KPC variants, while MVB may be considered in monotherapy. The detection of KPC variants in an endemic setting for KPC-Kp represents a worryingly emerging condition. The optimal therapeutic approach is still unknown and the development of meropenem resistance is of concern, which may lead to therapeutic failure in clinical practice. In these cases, the addition of fosfomycin to meropenem, or a more potent antibiotic, such as meropenem/vaborbactam, may be valuable therapeutic options. Little is known regarding outcomes and optimal therapeutic regimens of infections caused by Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) resistant to ceftazidime/avibactam (CZA) and susceptible to meropenem (MEM). Although susceptible to MEM in vitro, the possibility of developing MEM resistance overtime is a concern. We describe the clinical characteristics of patients with colonization/infection due to KPC variants with a focus on the in vitro activity of fosfomycin (FOS)-containing combinations.OBJECTIVESLittle is known regarding outcomes and optimal therapeutic regimens of infections caused by Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) resistant to ceftazidime/avibactam (CZA) and susceptible to meropenem (MEM). Although susceptible to MEM in vitro, the possibility of developing MEM resistance overtime is a concern. We describe the clinical characteristics of patients with colonization/infection due to KPC variants with a focus on the in vitro activity of fosfomycin (FOS)-containing combinations.Patients with colonization/infection due to a KPC variant were included. Fosfomycin susceptibility was performed by agar dilution method. Synergistic activity of FOS-based combinations was evaluated by gradient strip-agar diffusion method. The emergence of in vitro MEM resistance was also tested.METHODSPatients with colonization/infection due to a KPC variant were included. Fosfomycin susceptibility was performed by agar dilution method. Synergistic activity of FOS-based combinations was evaluated by gradient strip-agar diffusion method. The emergence of in vitro MEM resistance was also tested.Eleven patients were included: eight with infection [four with ventilator-associated pneumonia and four with bloodstream infections] and three with colonization. Previous therapy with CZA was administered to all patients (with a mean cumulative duration of 23 days). All subjects with infection received meropenem, in monotherapy (n = 4) or with amikacin (n = 2) or fosfomycin (n = 2), and achieved clinical cure. A new CZA-susceptible and MEM-resistant KPC-Kp strain was subsequently isolated in three patients (27.3%). Meropenem/vaborbactam (MVB) showed high in vitro activity, while FOS+MEM combination was synergistic in 40% of cases. In vitro resistance to MEM was observed with maintenance of CZA resistance.RESULTSEleven patients were included: eight with infection [four with ventilator-associated pneumonia and four with bloodstream infections] and three with colonization. Previous therapy with CZA was administered to all patients (with a mean cumulative duration of 23 days). All subjects with infection received meropenem, in monotherapy (n = 4) or with amikacin (n = 2) or fosfomycin (n = 2), and achieved clinical cure. A new CZA-susceptible and MEM-resistant KPC-Kp strain was subsequently isolated in three patients (27.3%). Meropenem/vaborbactam (MVB) showed high in vitro activity, while FOS+MEM combination was synergistic in 40% of cases. In vitro resistance to MEM was observed with maintenance of CZA resistance.Detection of KPC variants may occur within the same patient, especially if CZA has been previously administered. Although clinical success has been obtained with carbapenems, the emergence of MEM resistance is a concern. Fosfomycin plus meropenem is synergistic and may be a valuable combination option for KPC variants, while MVB may be considered in monotherapy. The detection of KPC variants in an endemic setting for KPC-Kp represents a worryingly emerging condition. The optimal therapeutic approach is still unknown and the development of meropenem resistance is of concern, which may lead to therapeutic failure in clinical practice. In these cases, the addition of fosfomycin to meropenem, or a more potent antibiotic, such as meropenem/vaborbactam, may be valuable therapeutic options.CONCLUSIONSDetection of KPC variants may occur within the same patient, especially if CZA has been previously administered. Although clinical success has been obtained with carbapenems, the emergence of MEM resistance is a concern. Fosfomycin plus meropenem is synergistic and may be a valuable combination option for KPC variants, while MVB may be considered in monotherapy. The detection of KPC variants in an endemic setting for KPC-Kp represents a worryingly emerging condition. The optimal therapeutic approach is still unknown and the development of meropenem resistance is of concern, which may lead to therapeutic failure in clinical practice. In these cases, the addition of fosfomycin to meropenem, or a more potent antibiotic, such as meropenem/vaborbactam, may be valuable therapeutic options. •Clinical characteristics and fosfomycin synergism of KPC-variants were investigated.•KPC-variant detection follows a previous CZA-susceptible KPC-Kp in the same patient.•Treatment with meropenem achieved clinical cure in all the patients.•Fosfomycin plus meropenem resulted in full synergism in 40% of cases.•FOS plus MEM may be an option for KPC-variant infections at low risk of mortality. Little is known regarding outcomes and optimal therapeutic regimens of infections caused by Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) resistant to ceftazidime/avibactam (CZA) and susceptible to meropenem (MEM). Although susceptible to MEM in vitro, the possibility of developing MEM resistance overtime is a concern. We describe the clinical characteristics of patients with colonization/infection due to KPC variants with a focus on the in vitro activity of fosfomycin (FOS)-containing combinations. Patients with colonization/infection due to a KPC variant were included. Fosfomycin susceptibility was performed by agar dilution method. Synergistic activity of FOS-based combinations was evaluated by gradient strip-agar diffusion method. The emergence of in vitro MEM resistance was also tested. Eleven patients were included: eight with infection [four with ventilator-associated pneumonia and four with bloodstream infections] and three with colonization. Previous therapy with CZA was administered to all patients (with a mean cumulative duration of 23 days). All subjects with infection received meropenem, in monotherapy (n = 4) or with amikacin (n = 2) or fosfomycin (n = 2), and achieved clinical cure. A new CZA-susceptible and MEM-resistant KPC-Kp strain was subsequently isolated in three patients (27.3%). Meropenem/vaborbactam (MVB) showed high in vitro activity, while FOS+MEM combination was synergistic in 40% of cases. In vitro resistance to MEM was observed with maintenance of CZA resistance. Detection of KPC variants may occur within the same patient, especially if CZA has been previously administered. Although clinical success has been obtained with carbapenems, the emergence of MEM resistance is a concern. Fosfomycin plus meropenem is synergistic and may be a valuable combination option for KPC variants, while MVB may be considered in monotherapy. The detection of KPC variants in an endemic setting for KPC-Kp represents a worryingly emerging condition. The optimal therapeutic approach is still unknown and the development of meropenem resistance is of concern, which may lead to therapeutic failure in clinical practice. In these cases, the addition of fosfomycin to meropenem, or a more potent antibiotic, such as meropenem/vaborbactam, may be valuable therapeutic options. Objectives: Little is known regarding outcomes and optimal therapeutic regimens of infections caused by Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) resistant to ceftazidime/avibactam (CZA) and susceptible to meropenem (MEM). Although susceptible to MEM in vitro, the possibility of developing MEM resistance overtime is a concern. We describe the clinical characteristics of patients with colonization/infection due to KPC variants with a focus on the in vitro activity of fosfomycin (FOS)-containing combinations. Methods: Patients with colonization/infection due to a KPC variant were included. Fosfomycin susceptibility was performed by agar dilution method. Synergistic activity of FOS-based combinations was evaluated by gradient strip-agar diffusion method. The emergence of in vitro MEM resistance was also tested. Results: Eleven patients were included: eight with infection [four with ventilator-associated pneumonia and four with bloodstream infections] and three with colonization. Previous therapy with CZA was administered to all patients (with a mean cumulative duration of 23 days). All subjects with infection received meropenem, in monotherapy (n = 4) or with amikacin (n = 2) or fosfomycin (n = 2), and achieved clinical cure. A new CZA-susceptible and MEM-resistant KPC-Kp strain was subsequently isolated in three patients (27.3%). Meropenem/vaborbactam (MVB) showed high in vitro activity, while FOS+MEM combination was synergistic in 40% of cases. In vitro resistance to MEM was observed with maintenance of CZA resistance. Conclusions: Detection of KPC variants may occur within the same patient, especially if CZA has been previously administered. Although clinical success has been obtained with carbapenems, the emergence of MEM resistance is a concern. Fosfomycin plus meropenem is synergistic and may be a valuable combination option for KPC variants, while MVB may be considered in monotherapy. The detection of KPC variants in an endemic setting for KPC-Kp represents a worryingly emerging condition. The optimal therapeutic approach is still unknown and the development of meropenem resistance is of concern, which may lead to therapeutic failure in clinical practice. In these cases, the addition of fosfomycin to meropenem, or a more potent antibiotic, such as meropenem/vaborbactam, may be valuable therapeutic options. Highlights•Clinical characteristics and fosfomycin synergism of KPC-variants were investigated. •KPC-variant detection follows a previous CZA-susceptible KPC-Kp in the same patient. •Treatment with meropenem achieved clinical cure in all the patients. •Fosfomycin plus meropenem resulted in full synergism in 40% of cases. •FOS plus MEM may be an option for KPC-variant infections at low risk of mortality. |
| Author | De Angelis, M. Mascellino, M.T. Oliva, A. Venditti, M Carattoli, A. Arcari, G. Sacco, F. Volpicelli, L. Casali, E. Raponi, G. Miele, MC Cancelli, F. Al Ismail, D. |
| Author_xml | – sequence: 1 givenname: A. orcidid: 0000-0003-0832-7975 surname: Oliva fullname: Oliva, A. email: alessandra.oliva@uniroma1.it organization: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy – sequence: 2 givenname: D. orcidid: 0000-0002-6277-5464 surname: Al Ismail fullname: Al Ismail, D. organization: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy – sequence: 3 givenname: G. surname: Arcari fullname: Arcari, G. organization: Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy – sequence: 4 givenname: MC surname: Miele fullname: Miele, MC organization: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy – sequence: 5 givenname: E. surname: Casali fullname: Casali, E. organization: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy – sequence: 6 givenname: F. surname: Sacco fullname: Sacco, F. organization: Microbiology and Virology Unit, University Hospital Policlinico Umberto I, Rome, Italy – sequence: 7 givenname: L. surname: Volpicelli fullname: Volpicelli, L. organization: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy – sequence: 8 givenname: M. surname: De Angelis fullname: De Angelis, M. organization: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy – sequence: 9 givenname: M.T. orcidid: 0000-0001-7684-3088 surname: Mascellino fullname: Mascellino, M.T. organization: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy – sequence: 10 givenname: F. orcidid: 0000-0003-4801-3292 surname: Cancelli fullname: Cancelli, F. organization: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy – sequence: 11 givenname: G. orcidid: 0000-0002-9665-0811 surname: Raponi fullname: Raponi, G. organization: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy – sequence: 12 givenname: A. orcidid: 0000-0002-6120-6526 surname: Carattoli fullname: Carattoli, A. organization: Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy – sequence: 13 givenname: M surname: Venditti fullname: Venditti, M organization: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37086891$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUl1rFDEUHaRia-0f8EHm0ZfZJpmdryJCWfwoLSioz-Emc1PuOpOsSWZh_WH-PjO7bR8KVriQcLnnHDjnvMyOrLOYZa85W3DG6_P1Yn0LfiGYKBcsDRfPshMheFk0vCmPHv51dZydhUCKVawpy3rJXmTHZcPauu34SfZnhSbCb-ppxHPYkgIdYSw8BgoRbMxH9G6DFsciTEHjJpIaML_-uio23vWTJnubXw-oAuEwQL6xOI3OEuBFfmlh2CWe3JlcQ8CQg-1z3MIwQSRn5z3ZfEvRuzzpUvrt5qVxwbhxl7gL7WwEsrOKdqMiu0eGV9lzA0PAs7v3NPvx8cP31efi5sunq9XlTaGrRsTC9K1eaiiXUHeGg-EcRctV1xvRma5mChRD0XQCe1NWlapbsWzRtAzrjjXLrjzNrg68vYO13Hgawe-kA5L7hfO3EnwkPaDkYmkU74zSjV6WQiie2Os0LTPATJ243h64knG_JgxRjpQcTa5ZdFOQok0RiarqeDp9c3c6qRH7B-H73NJBezjQ3oXg0UhNcW9N9ECD5EzOLZFrObdEzi2RLA0XCSoeQe_ZnwS9O4Awmb0l9DJoQquxJ486Jjfoafj7R3A9pFA1DD9xh2HtJp-6EiSXQUgmv83dnasrSsZY1c45XPyb4H_qfwENBAN0 |
| CitedBy_id | crossref_primary_10_1093_ofid_ofad327 crossref_primary_10_1080_1120009X_2024_2349439 crossref_primary_10_3390_jcm12247693 crossref_primary_10_1016_j_jddst_2023_104874 crossref_primary_10_1093_jac_dkae389 crossref_primary_10_1016_j_ijantimicag_2024_107364 crossref_primary_10_1016_j_ijantimicag_2024_107365 crossref_primary_10_1016_j_jgar_2024_03_003 crossref_primary_10_1093_jac_dkae253 |
| Cites_doi | 10.1016/S1473-3099(17)30228-1 10.2147/IDR.S343673 10.1016/j.jgar.2019.11.007 10.1093/cid/ciw243 10.1093/ofid/ofab141 10.1080/22221751.2021.1984182 10.1093/jac/dkaa503 10.3389/fcimb.2022.1010979 10.1128/AAC.02534-16 10.3390/antibiotics9080500 10.1093/ofid/ofx101 10.1016/j.jgar.2019.12.009 10.1128/AAC.00574-21 10.1128/AAC.00890-21 10.1016/j.ijantimicag.2022.106671 10.1093/cid/ciy492 10.1016/j.idc.2020.05.001 10.3390/jfb13040174 10.1016/j.ijantimicag.2009.01.015 10.1016/j.cmi.2021.03.001 10.1007/s40121-020-00344-z 10.1016/j.jiac.2021.01.014 10.1007/s10096-021-04388-y 10.3390/antibiotics10121475 10.1080/1120009X.2021.1909939 10.1128/AAC.01086-10 10.1128/AAC.02313-19 10.1128/AAC.02497-17 10.1016/j.cmi.2019.08.020 10.1128/AAC.00079-17 10.1093/cid/ciab176 10.1016/j.jgar.2021.04.001 10.1128/AAC.01936-19 10.1016/j.cmi.2019.11.011 10.3390/antibiotics10070781 10.1080/1120009X.2022.2031471 10.1016/j.ijantimicag.2022.106611 10.1007/s10096-021-04341-z |
| ContentType | Journal Article |
| Copyright | 2023 The Authors The Authors Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. |
| Copyright_xml | – notice: 2023 The Authors – notice: The Authors – notice: Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 DOA |
| DOI | 10.1016/j.jgar.2023.03.012 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: Open Access资源_DOAJ url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2213-7173 |
| EndPage | 327 |
| ExternalDocumentID | oai_doaj_org_article_124fb19fbc7c4322b1bab6ab680fa0f6 37086891 10_1016_j_jgar_2023_03_012 S2213716523000589 1_s2_0_S2213716523000589 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | ALMA_UNASSIGNED_HOLDINGS M~E --M .1- .FO .~1 0R~ 1~. 4.4 457 4G. 53G 7-5 8P~ AAAJQ AABSN AACTN AAEDT AAEDW AAHOK AAIKJ AAKOC AALRI AAOAW AAQFI AAXKI AAXUO ABJNI ABMAC ABMZM ABXDB ACDAQ ACGFS ACRLP ADBBV ADEZE ADVLN AEBSH AEIPS AEKER AENEX AFCTW AFJKZ AFKWA AFRHN AFTJW AFXIZ AGEKW AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK AMFUW AMRAJ ANKPU ANZVX AXJTR BKOJK BLXMC BNPGV CJTIS COPKO EBS EFJIC EJD FDB FEDTE FIRID FNPLU FYGXN GBLVA GROUPED_DOAJ HVGLF HZ~ KOM LUGTX M41 MO0 NCXOZ O-L O9- OAUVE OK1 P-8 P-9 PC. Q38 RIG ROL SDF SPCBC SSH SSI SSZ T5K Z5R ~G- 6I. AAFTH AAIAV ABLVK ABYKQ AJBFU EFLBG LCYCR AATTM AAYWO AAYXX ACIEU ACVFH ADCNI AEUPX AFPUW AGCQF AGRNS AIGII AIIUN AKBMS AKYEP APXCP CITATION CGR CUY CVF ECM EFKBS EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c572t-fd8c4ca34a69f1af11e281b9df29f960bab0e2792edf355b68248ef80e6907493 |
| IEDL.DBID | DOA |
| ISSN | 2213-7165 2213-7173 |
| IngestDate | Wed Aug 27 01:26:46 EDT 2025 Fri Jul 11 07:28:02 EDT 2025 Mon Jul 21 05:51:34 EDT 2025 Tue Jul 01 03:34:48 EDT 2025 Thu Apr 24 23:04:31 EDT 2025 Fri Feb 23 02:37:44 EST 2024 Tue Feb 25 20:01:08 EST 2025 Tue Aug 26 16:34:45 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Meropenem/vaborbactam Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae KPC-variant Carbapenems Synergism Fosfomycin |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c572t-fd8c4ca34a69f1af11e281b9df29f960bab0e2792edf355b68248ef80e6907493 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-6277-5464 0000-0002-9665-0811 0000-0003-0832-7975 0000-0002-6120-6526 0000-0003-4801-3292 0000-0001-7684-3088 |
| OpenAccessLink | https://doaj.org/article/124fb19fbc7c4322b1bab6ab680fa0f6 |
| PMID | 37086891 |
| PQID | 2805025591 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_124fb19fbc7c4322b1bab6ab680fa0f6 proquest_miscellaneous_2805025591 pubmed_primary_37086891 crossref_citationtrail_10_1016_j_jgar_2023_03_012 crossref_primary_10_1016_j_jgar_2023_03_012 elsevier_sciencedirect_doi_10_1016_j_jgar_2023_03_012 elsevier_clinicalkeyesjournals_1_s2_0_S2213716523000589 elsevier_clinicalkey_doi_10_1016_j_jgar_2023_03_012 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-06-01 |
| PublicationDateYYYYMMDD | 2023-06-01 |
| PublicationDate_xml | – month: 06 year: 2023 text: 2023-06-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Journal of Global Antimicrobial Resistance |
| PublicationTitleAlternate | J Glob Antimicrob Resist |
| PublicationYear | 2023 |
| Publisher | Elsevier Ltd Elsevier |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier |
| References | Guo, Liu, Lin, Ba, Zhuo, Li (bib0016) 2021; 10 Shields, Chen, Cheng, Chavda, Press, Snyder (bib0020) 2017; 61 Du, Mu, Liu, Yuan, Zhu, Ma (bib0025) 2022; 15 Gutiérrez-Gutiérrez, Salamanca, de Cueto, Hsueh, Viale, Paño-Pardo (bib0033) 2017; 17 Karaiskos, Daikos, Gkoufa, Adamis, Stefos, Symbardi (bib0001) 2021; 76 Cano, Guzmán-Puche, García-Gutiérrez, Castón, Gracia-Ahufinger, Pérez-Nadales (bib0023) 2020; 22 van Asten, Boattini, Kraakman, Bianco, Iannaccone, Costa (bib0024) 2021; 27 Tiseo, Brigante, Giacobbe, Maraolo, Gona, Falcone (bib0037) 2022; 60 Arcari, Oliva, Sacco, Di Lella, Raponi, Tomolillo (bib0043) 2022; 41 Bongiorno, Bivona, Cicino, Trecarichi, Russo, Marascio (bib0026) 2023; 12 [accessed 27.12.22]. Tumbarello, Raffaelli, Giannella, Mantengoli, Mularoni, Venditti (bib0009) 2021; 73 Di Bella, Giacobbe, Maraolo, Viaggi, Luzzati, Bassetti (bib0007) 2021; 25 Findlay, Poirel, Juhas, Nordmann (bib0015) 2021; 65 Di Pilato, Principe, Andriani (bib0035) 2022; 19 European Committee on Antimicrobial Susceptibility Testing (EUCAST) website. Clinical breakpoints – bacteria Ackley, Roshdy, Meredith, Minor, Anderson, Capraro (bib0031) 2020; 64 Papp-Wallace, Mack, Taracila, Bonomo (bib0013) 2020; 34 Tsivkovski, Lomovskaya (bib0032) 2020; 64 Haidar, Clancy, Shields, Hao, Cheng, Nguyen (bib0017) 2017; 61 Tiseo, Falcone, Leonildi, Giordano, Barnini, Arcari (bib0005) 2021; 8 Shields, Nguyen, Press, Chen, Kreiswirth, Clancy (bib0019) 2017; 61 van Duin, Bonomo (bib0003) 2016; 63 Gaibani, Re, Campoli, Viale, Ambretti (bib0010) 2020; 26 Shields, Nguyen, Chen, Press, Kreiswirth, Clancy (bib0004) 2018; 62 Zhang, Shi, Hu, Hong, Wu, Du (bib0008) 2020; 26 Wang, Zhao, Liu, Sun, Sun, Li (bib0044) 2021; 12 Carattoli, Arcari, Bibbolino, Sacco, Tomolillo, Di Lella (bib0012) 2021; 65 Antonello, Principe, Maraolo, Viaggi, Pol, Fabbiani (bib0022) 2020; 9 Arcari, Polani, Bruno, Capitani, Sacco, Menichincheri (bib0028) 2023; 9 Souli, Galani, Boukovalas, Gourgoulis, Chryssouli, Kanellakopoulou (bib0040) 2011; 55 Bianco, Boattini, Comini, Iannaccone, Casale, Allizond (bib0034) 2022; 34 Lupia, Corcione, Shbaklo, Montrucchio, De Benedetto, Fornari (bib0036) 2022; 13 Bianco, Boattini, Comini, Iannaccone, Bondi, Cavallo (bib0038) 2022; 41 Boattini, Bianco, Iannaccone, Bondi, Cavallo, Costa (bib0042) 2021; 33 Oliva, Volpicelli, Di Bari, Curtolo, Borrazzo, Cogliati Dezza (bib0011) 2020; 4 Venditti, Butera, Meledandri, Balice, Cocciolillo, Fontana (bib0018) 2021; 27 Gaibani, Crovara-Pesce, Lazzarotto, Pea, Ambretti (bib0041) 2022; 60 Wenzler, Scoble (bib0030) 2020; 9 Wang, Wang, Wang, Cai (bib0014) 2020; 22 Volpicelli, Venditti, Ceccarelli, Oliva (bib0029) 2021; 10 Burkhardt, Rauch, Kaever, Hadem, Kielstein, Welte (bib0039) 2009; 34 Tumbarello, Trecarichi, Corona, De Rosa, Bassetti, Mussini (bib0002) 2019; 68 Oliva, Curtolo, Volpicelli, Cogliati Dezza, De Angelis, Cairoli (bib0006) 2021; 10 Shields, Nguyen, Press, Chen, Kreiswirth, Clancy (bib0021) 2017; 4 van Asten (10.1016/j.jgar.2023.03.012_bib0024) 2021; 27 Bianco (10.1016/j.jgar.2023.03.012_bib0038) 2022; 41 10.1016/j.jgar.2023.03.012_bib0027 Gaibani (10.1016/j.jgar.2023.03.012_bib0010) 2020; 26 Shields (10.1016/j.jgar.2023.03.012_bib0021) 2017; 4 Wenzler (10.1016/j.jgar.2023.03.012_bib0030) 2020; 9 Tiseo (10.1016/j.jgar.2023.03.012_bib0005) 2021; 8 Findlay (10.1016/j.jgar.2023.03.012_bib0015) 2021; 65 Wang (10.1016/j.jgar.2023.03.012_bib0014) 2020; 22 Volpicelli (10.1016/j.jgar.2023.03.012_bib0029) 2021; 10 Shields (10.1016/j.jgar.2023.03.012_bib0020) 2017; 61 Karaiskos (10.1016/j.jgar.2023.03.012_bib0001) 2021; 76 Shields (10.1016/j.jgar.2023.03.012_bib0019) 2017; 61 Tumbarello (10.1016/j.jgar.2023.03.012_bib0009) 2021; 73 van Duin (10.1016/j.jgar.2023.03.012_bib0003) 2016; 63 Burkhardt (10.1016/j.jgar.2023.03.012_bib0039) 2009; 34 Gaibani (10.1016/j.jgar.2023.03.012_bib0041) 2022; 60 Tumbarello (10.1016/j.jgar.2023.03.012_bib0002) 2019; 68 Ackley (10.1016/j.jgar.2023.03.012_bib0031) 2020; 64 Arcari (10.1016/j.jgar.2023.03.012_bib0043) 2022; 41 Di Bella (10.1016/j.jgar.2023.03.012_bib0007) 2021; 25 Guo (10.1016/j.jgar.2023.03.012_bib0016) 2021; 10 Di Pilato (10.1016/j.jgar.2023.03.012_bib0035) 2022; 19 Shields (10.1016/j.jgar.2023.03.012_bib0004) 2018; 62 Oliva (10.1016/j.jgar.2023.03.012_bib0006) 2021; 10 Venditti (10.1016/j.jgar.2023.03.012_bib0018) 2021; 27 Arcari (10.1016/j.jgar.2023.03.012_bib0028) 2023; 9 Lupia (10.1016/j.jgar.2023.03.012_bib0036) 2022; 13 Carattoli (10.1016/j.jgar.2023.03.012_bib0012) 2021; 65 Oliva (10.1016/j.jgar.2023.03.012_bib0011) 2020; 4 Cano (10.1016/j.jgar.2023.03.012_bib0023) 2020; 22 Du (10.1016/j.jgar.2023.03.012_bib0025) 2022; 15 Papp-Wallace (10.1016/j.jgar.2023.03.012_bib0013) 2020; 34 Wang (10.1016/j.jgar.2023.03.012_bib0044) 2021; 12 Tsivkovski (10.1016/j.jgar.2023.03.012_bib0032) 2020; 64 Bianco (10.1016/j.jgar.2023.03.012_bib0034) 2022; 34 Zhang (10.1016/j.jgar.2023.03.012_bib0008) 2020; 26 Antonello (10.1016/j.jgar.2023.03.012_bib0022) 2020; 9 Souli (10.1016/j.jgar.2023.03.012_bib0040) 2011; 55 Bongiorno (10.1016/j.jgar.2023.03.012_bib0026) 2023; 12 Tiseo (10.1016/j.jgar.2023.03.012_bib0037) 2022; 60 Boattini (10.1016/j.jgar.2023.03.012_bib0042) 2021; 33 Haidar (10.1016/j.jgar.2023.03.012_bib0017) 2017; 61 Gutiérrez-Gutiérrez (10.1016/j.jgar.2023.03.012_bib0033) 2017; 17 |
| References_xml | – volume: 63 start-page: 234 year: 2016 end-page: 241 ident: bib0003 article-title: Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations publication-title: Clin Infect Dis – volume: 26 start-page: 516.e1 year: 2020 end-page: 516.e4 ident: bib0010 article-title: Bloodstream infection caused by KPC-producing publication-title: Clin Microbiol Infect – volume: 22 start-page: 18 year: 2020 end-page: 27 ident: bib0014 article-title: Resistance to ceftazidime-avibactam and underlying mechanisms publication-title: J Glob Antimicrob Resist – volume: 64 year: 2020 ident: bib0032 article-title: Potency of vaborbactam is less affected than that of avibactam in strains producing KPC-2 mutations that confer resistance to ceftazidime-avibactam publication-title: Antimicrob Agents Chemother – volume: 22 start-page: 9 year: 2020 end-page: 12 ident: bib0023 article-title: Use of carbapenems in the combined treatment of emerging ceftazidime/avibactam-resistant and carbapenem-susceptible KPC-producing publication-title: J Glob Antimicrob Resist – volume: 65 year: 2021 ident: bib0012 article-title: Evolutionary trajectories toward ceftazidime-avibactam resistance in publication-title: Antimicrob Agents Chemother – volume: 62 year: 2018 ident: bib0004 article-title: Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections publication-title: Antimicrob Agents Chemother – volume: 9 start-page: 500 year: 2020 ident: bib0022 article-title: Fosfomycin as partner drug for systemic infection management. A systematic review of its synergistic properties from in vitro and in vivo studies publication-title: Antibiotics (Basel) – volume: 10 start-page: 2042 year: 2021 end-page: 2051 ident: bib0016 article-title: Mutations in porin LamB contribute to ceftazidime-avibactam resistance in KPC-producing publication-title: Emerg Microbes Infect – volume: 10 start-page: 1475 year: 2021 ident: bib0029 article-title: Place in therapy of the newly available armamentarium for multi-drug-resistant Gram-negative pathogens: proposal of a prescription algorithm publication-title: Antibiotics (Basel) – volume: 64 start-page: e02313 year: 2020 end-page: e02319 ident: bib0031 article-title: Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae infections publication-title: Antimicrob Agents Chemother – volume: 19 year: 2022 ident: bib0035 article-title: Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by publication-title: Clin Microbiol Infect – volume: 9 start-page: 769 year: 2020 end-page: 784 ident: bib0030 article-title: An appraisal of the pharmacokinetic and pharmacodynamic properties of mero-penem-vaborbactam publication-title: Infect Dis Ther – volume: 73 start-page: 1664 year: 2021 end-page: 1676 ident: bib0009 article-title: Ceftazidime-avibactam use for publication-title: Clin Infect Dis – volume: 41 start-page: 63 year: 2022 end-page: 70 ident: bib0038 article-title: In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects publication-title: Eur J Clin Microbiol Infect Dis – volume: 34 start-page: 773 year: 2020 end-page: 819 ident: bib0013 article-title: Resistance to novel β-lactam-β-lactamase inhibitor combi-nations: the “price of progress” publication-title: Infect Dis Clin North Am – volume: 9 year: 2023 ident: bib0028 article-title: Ceftazidime-avibactam resistance in publication-title: Microb Genom – volume: 13 start-page: 174 year: 2022 ident: bib0036 article-title: Meropenem/vaborbactam and cefiderocol as combination or monotherapy to treat multi-drug resistant Gram-negative infections: a regional cross-sectional survey from Piedmont Infectious Disease Unit Network (PIDUN) publication-title: J Funct Biomater – volume: 10 start-page: 781 year: 2021 ident: bib0006 article-title: Synergistic meropenem/vaborbactam plus fosfomycin treatment of KPC producing publication-title: Antibiotics (Basel) – volume: 17 start-page: 726 year: 2017 end-page: 734 ident: bib0033 article-title: Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study publication-title: Lancet Infect Dis – reference: ; [accessed 27.12.22]. – volume: 61 year: 2017 ident: bib0017 article-title: Mutations in publication-title: Antimicrob Agents Chemother – volume: 60 year: 2022 ident: bib0037 article-title: Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM) publication-title: Int J Antimicrob Agents – volume: 4 year: 2020 ident: bib0011 article-title: Effect of ceftazidime/avibactam plus fosfomycin combination on 30 day mortality in patients with bloodstream infections caused by KPC-producing publication-title: JAC Antimicrob Resist – volume: 76 start-page: 775 year: 2021 end-page: 783 ident: bib0001 article-title: Ceftazidime/avibactam in the era of carbapenemase-producing publication-title: J Antimicrob Chemother – volume: 15 start-page: 69 year: 2022 end-page: 81 ident: bib0025 article-title: The genomic characterization of KPC-producing publication-title: Infect Drug Resist – volume: 4 start-page: ofx101 year: 2017 ident: bib0021 article-title: Emergence of ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in publication-title: Open Forum Infect Dis – volume: 12 year: 2021 ident: bib0044 article-title: In vivo selection of imipenem resistance among ceftazidime-avibactam-resistant, imipenem-susceptible publication-title: Front Microbiol – volume: 33 start-page: 598 year: 2021 end-page: 600 ident: bib0042 article-title: Looking beyond ceftazidime-avibactam resistance in KPC-producing publication-title: J Chemother – volume: 27 start-page: 1040.e1 year: 2021 end-page: 1040.e6 ident: bib0018 article-title: Molecular analysis of clinical isolates of ceftazidime-avibactam-resistant publication-title: Clin Microbiol Infect – volume: 65 year: 2021 ident: bib0015 article-title: KPC-mediated resistance to ceftazidime-avibactam and collateral effects in publication-title: Antimicrob Agents Chemother – volume: 34 start-page: 302 year: 2022 end-page: 310 ident: bib0034 article-title: Activity of ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol and comparators against Gram-negative organisms causing bloodstream infections in Northern Italy (2019-2021): emergence of complex resistance phenotypes publication-title: J Chemother – volume: 8 start-page: ofab141 year: 2021 ident: bib0005 article-title: Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-, cefiderocol-resistant ST-512 publication-title: Open Forum Infect Dis – volume: 12 year: 2023 ident: bib0026 article-title: Omic insights into various ceftazidime-avibactam-resistant publication-title: Front Cell Infect Microbiol – volume: 27 start-page: 778 year: 2021 end-page: 780 ident: bib0024 article-title: Ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in KPC-producing publication-title: J Infect Chemother – volume: 68 start-page: 355 year: 2019 end-page: 364 ident: bib0002 article-title: Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by publication-title: Clin Infect Dis – volume: 25 start-page: 268 year: 2021 end-page: 281 ident: bib0007 article-title: Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies publication-title: J Glob Antimicrob Resist – volume: 61 year: 2017 ident: bib0020 article-title: Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem resistant publication-title: Antimicrob Agents Chemother – volume: 34 start-page: 101 year: 2009 end-page: 102 ident: bib0039 article-title: Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint publication-title: Int J Antimicrob Agents – volume: 26 start-page: 124.e1 year: 2020 end-page: 124.e4 ident: bib0008 article-title: Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China publication-title: Clin Microbiol Infect – reference: European Committee on Antimicrobial Susceptibility Testing (EUCAST) website. Clinical breakpoints – bacteria, – volume: 60 year: 2022 ident: bib0041 article-title: Evaluation of synergistic activity of fosfomycin in combination with novel ß-lactams/ß-lactamase inhibitor combinations (βL-βLICs) against KPC-producing publication-title: Int J Antimicrob Agents – volume: 55 start-page: 2395 year: 2011 end-page: 2397 ident: bib0040 article-title: In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing publication-title: Antimicrob Agents Chemother – volume: 41 start-page: 495 year: 2022 end-page: 500 ident: bib0043 article-title: Interplay between publication-title: Eur J Clin Microbiol Infect Dis – volume: 61 year: 2017 ident: bib0019 article-title: In vitro selection of meropenem resistance among ceftazidime-avibactam-resistant, meropenemsusceptible publication-title: Antimicrob Agents Chemother – volume: 17 start-page: 726 year: 2017 ident: 10.1016/j.jgar.2023.03.012_bib0033 article-title: Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(17)30228-1 – volume: 15 start-page: 69 year: 2022 ident: 10.1016/j.jgar.2023.03.012_bib0025 article-title: The genomic characterization of KPC-producing Klebsiella pneumoniae from the ICU of a teaching hospital in Shanghai, China publication-title: Infect Drug Resist doi: 10.2147/IDR.S343673 – volume: 22 start-page: 9 year: 2020 ident: 10.1016/j.jgar.2023.03.012_bib0023 article-title: Use of carbapenems in the combined treatment of emerging ceftazidime/avibactam-resistant and carbapenem-susceptible KPC-producing Klebsiella pneumoniae infections: report of a case and review of the literature publication-title: J Glob Antimicrob Resist doi: 10.1016/j.jgar.2019.11.007 – volume: 63 start-page: 234 year: 2016 ident: 10.1016/j.jgar.2023.03.012_bib0003 article-title: Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations publication-title: Clin Infect Dis doi: 10.1093/cid/ciw243 – volume: 8 start-page: ofab141 year: 2021 ident: 10.1016/j.jgar.2023.03.012_bib0005 article-title: Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-, cefiderocol-resistant ST-512 Klebsiella pneumoniae-producing KPC-31, a D179Y variant of KPC-3 publication-title: Open Forum Infect Dis doi: 10.1093/ofid/ofab141 – volume: 10 start-page: 2042 year: 2021 ident: 10.1016/j.jgar.2023.03.012_bib0016 article-title: Mutations in porin LamB contribute to ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae publication-title: Emerg Microbes Infect doi: 10.1080/22221751.2021.1984182 – volume: 61 year: 2017 ident: 10.1016/j.jgar.2023.03.012_bib0020 article-title: Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem resistant Klebsiella pneumoniae infections publication-title: Antimicrob Agents Chemother – volume: 76 start-page: 775 year: 2021 ident: 10.1016/j.jgar.2023.03.012_bib0001 article-title: Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkaa503 – volume: 12 year: 2023 ident: 10.1016/j.jgar.2023.03.012_bib0026 article-title: Omic insights into various ceftazidime-avibactam-resistant Klebsiella pneumoniae isolates from two southern Italian regions publication-title: Front Cell Infect Microbiol doi: 10.3389/fcimb.2022.1010979 – volume: 61 year: 2017 ident: 10.1016/j.jgar.2023.03.012_bib0017 article-title: Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum β-lactamases publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.02534-16 – volume: 9 start-page: 500 year: 2020 ident: 10.1016/j.jgar.2023.03.012_bib0022 article-title: Fosfomycin as partner drug for systemic infection management. A systematic review of its synergistic properties from in vitro and in vivo studies publication-title: Antibiotics (Basel) doi: 10.3390/antibiotics9080500 – volume: 4 start-page: ofx101 year: 2017 ident: 10.1016/j.jgar.2023.03.012_bib0021 article-title: Emergence of ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in Klebsiella pneumoniae carbapenemase-producing K pneumoniae: a case report and review of literature publication-title: Open Forum Infect Dis doi: 10.1093/ofid/ofx101 – volume: 22 start-page: 18 year: 2020 ident: 10.1016/j.jgar.2023.03.012_bib0014 article-title: Resistance to ceftazidime-avibactam and underlying mechanisms publication-title: J Glob Antimicrob Resist doi: 10.1016/j.jgar.2019.12.009 – volume: 4 year: 2020 ident: 10.1016/j.jgar.2023.03.012_bib0011 article-title: Effect of ceftazidime/avibactam plus fosfomycin combination on 30 day mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae: results from a multicentre retrospective study publication-title: JAC Antimicrob Resist – volume: 65 year: 2021 ident: 10.1016/j.jgar.2023.03.012_bib0012 article-title: Evolutionary trajectories toward ceftazidime-avibactam resistance in Klebsiella pneumoniae clinical isolates publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00574-21 – volume: 65 year: 2021 ident: 10.1016/j.jgar.2023.03.012_bib0015 article-title: KPC-mediated resistance to ceftazidime-avibactam and collateral effects in Klebsiella pneumoniae publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00890-21 – volume: 60 year: 2022 ident: 10.1016/j.jgar.2023.03.012_bib0041 article-title: Evaluation of synergistic activity of fosfomycin in combination with novel ß-lactams/ß-lactamase inhibitor combinations (βL-βLICs) against KPC-producing Klebsiella pneumoniae clinical isolates publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2022.106671 – ident: 10.1016/j.jgar.2023.03.012_bib0027 – volume: 68 start-page: 355 year: 2019 ident: 10.1016/j.jgar.2023.03.012_bib0002 article-title: Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae publication-title: Clin Infect Dis doi: 10.1093/cid/ciy492 – volume: 34 start-page: 773 year: 2020 ident: 10.1016/j.jgar.2023.03.012_bib0013 article-title: Resistance to novel β-lactam-β-lactamase inhibitor combi-nations: the “price of progress” publication-title: Infect Dis Clin North Am doi: 10.1016/j.idc.2020.05.001 – volume: 13 start-page: 174 year: 2022 ident: 10.1016/j.jgar.2023.03.012_bib0036 article-title: Meropenem/vaborbactam and cefiderocol as combination or monotherapy to treat multi-drug resistant Gram-negative infections: a regional cross-sectional survey from Piedmont Infectious Disease Unit Network (PIDUN) publication-title: J Funct Biomater doi: 10.3390/jfb13040174 – volume: 34 start-page: 101 year: 2009 ident: 10.1016/j.jgar.2023.03.012_bib0039 article-title: Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2009.01.015 – volume: 27 start-page: 1040.e1 year: 2021 ident: 10.1016/j.jgar.2023.03.012_bib0018 article-title: Molecular analysis of clinical isolates of ceftazidime-avibactam-resistant Klebsiella pneumoniae publication-title: Clin Microbiol Infect doi: 10.1016/j.cmi.2021.03.001 – volume: 9 start-page: 769 year: 2020 ident: 10.1016/j.jgar.2023.03.012_bib0030 article-title: An appraisal of the pharmacokinetic and pharmacodynamic properties of mero-penem-vaborbactam publication-title: Infect Dis Ther doi: 10.1007/s40121-020-00344-z – volume: 27 start-page: 778 year: 2021 ident: 10.1016/j.jgar.2023.03.012_bib0024 article-title: Ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in KPC-producing Klebsiella pneumoniae infections: a case series publication-title: J Infect Chemother doi: 10.1016/j.jiac.2021.01.014 – volume: 41 start-page: 495 year: 2022 ident: 10.1016/j.jgar.2023.03.012_bib0043 article-title: Interplay between Klebsiella pneumoniae producing KPC-31 and KPC-3 under treatment with high dosage meropenem: a case report publication-title: Eur J Clin Microbiol Infect Dis doi: 10.1007/s10096-021-04388-y – volume: 19 year: 2022 ident: 10.1016/j.jgar.2023.03.012_bib0035 article-title: Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam publication-title: Clin Microbiol Infect – volume: 10 start-page: 1475 year: 2021 ident: 10.1016/j.jgar.2023.03.012_bib0029 article-title: Place in therapy of the newly available armamentarium for multi-drug-resistant Gram-negative pathogens: proposal of a prescription algorithm publication-title: Antibiotics (Basel) doi: 10.3390/antibiotics10121475 – volume: 33 start-page: 598 year: 2021 ident: 10.1016/j.jgar.2023.03.012_bib0042 article-title: Looking beyond ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae: in vitro activity of the novel meropenemvaborbactam in combination with the old Fosfomycin publication-title: J Chemother doi: 10.1080/1120009X.2021.1909939 – volume: 55 start-page: 2395 year: 2011 ident: 10.1016/j.jgar.2023.03.012_bib0040 article-title: In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01086-10 – volume: 64 start-page: e02313 year: 2020 ident: 10.1016/j.jgar.2023.03.012_bib0031 article-title: Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae infections publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.02313-19 – volume: 62 year: 2018 ident: 10.1016/j.jgar.2023.03.012_bib0004 article-title: Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.02497-17 – volume: 26 start-page: 124.e1 year: 2020 ident: 10.1016/j.jgar.2023.03.012_bib0008 article-title: Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China publication-title: Clin Microbiol Infect doi: 10.1016/j.cmi.2019.08.020 – volume: 61 year: 2017 ident: 10.1016/j.jgar.2023.03.012_bib0019 article-title: In vitro selection of meropenem resistance among ceftazidime-avibactam-resistant, meropenemsusceptible Klebsiella pneumoniae isolates with variant KPC-3 carbapenemases publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00079-17 – volume: 9 year: 2023 ident: 10.1016/j.jgar.2023.03.012_bib0028 article-title: Ceftazidime-avibactam resistance in Klebsiella pneumoniae sequence type 37: a decade of persistence and concealed evolution publication-title: Microb Genom – volume: 12 year: 2021 ident: 10.1016/j.jgar.2023.03.012_bib0044 article-title: In vivo selection of imipenem resistance among ceftazidime-avibactam-resistant, imipenem-susceptible Klebsiella pneumoniae isolate with KPC-33 carbapenemase publication-title: Front Microbiol – volume: 73 start-page: 1664 year: 2021 ident: 10.1016/j.jgar.2023.03.012_bib0009 article-title: Ceftazidime-avibactam use for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae infections: a retrospective observational multicenter study publication-title: Clin Infect Dis doi: 10.1093/cid/ciab176 – volume: 25 start-page: 268 year: 2021 ident: 10.1016/j.jgar.2023.03.012_bib0007 article-title: Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies publication-title: J Glob Antimicrob Resist doi: 10.1016/j.jgar.2021.04.001 – volume: 64 year: 2020 ident: 10.1016/j.jgar.2023.03.012_bib0032 article-title: Potency of vaborbactam is less affected than that of avibactam in strains producing KPC-2 mutations that confer resistance to ceftazidime-avibactam publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01936-19 – volume: 26 start-page: 516.e1 year: 2020 ident: 10.1016/j.jgar.2023.03.012_bib0010 article-title: Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization publication-title: Clin Microbiol Infect doi: 10.1016/j.cmi.2019.11.011 – volume: 10 start-page: 781 year: 2021 ident: 10.1016/j.jgar.2023.03.012_bib0006 article-title: Synergistic meropenem/vaborbactam plus fosfomycin treatment of KPC producing K. pneumoniae septic thrombosis unresponsive to ceftazidime/avibactam: from the bench to the bedside publication-title: Antibiotics (Basel) doi: 10.3390/antibiotics10070781 – volume: 34 start-page: 302 year: 2022 ident: 10.1016/j.jgar.2023.03.012_bib0034 article-title: Activity of ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol and comparators against Gram-negative organisms causing bloodstream infections in Northern Italy (2019-2021): emergence of complex resistance phenotypes publication-title: J Chemother doi: 10.1080/1120009X.2022.2031471 – volume: 60 year: 2022 ident: 10.1016/j.jgar.2023.03.012_bib0037 publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2022.106611 – volume: 41 start-page: 63 year: 2022 ident: 10.1016/j.jgar.2023.03.012_bib0038 article-title: In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects publication-title: Eur J Clin Microbiol Infect Dis doi: 10.1007/s10096-021-04341-z |
| SSID | ssib050733640 ssj0000941267 |
| Score | 2.3158772 |
| Snippet | •Clinical characteristics and fosfomycin synergism of KPC-variants were investigated.•KPC-variant detection follows a previous CZA-susceptible KPC-Kp in the... Highlights•Clinical characteristics and fosfomycin synergism of KPC-variants were investigated. •KPC-variant detection follows a previous CZA-susceptible... Little is known regarding outcomes and optimal therapeutic regimens of infections caused by Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae... Little is known regarding outcomes and optimal therapeutic regimens of infections caused by Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae... Objectives: Little is known regarding outcomes and optimal therapeutic regimens of infections caused by Klebsiella pneumoniae carbapenemase-producing... |
| SourceID | doaj proquest pubmed crossref elsevier |
| SourceType | Open Website Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 321 |
| SubjectTerms | Agar - therapeutic use Carbapenems Ceftazidime - therapeutic use Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae KPC-variant Fosfomycin Fosfomycin - pharmacology Fosfomycin - therapeutic use Humans Infectious Disease Klebsiella Infections - drug therapy Klebsiella pneumoniae Meropenem - pharmacology Meropenem - therapeutic use Meropenem/vaborbactam Synergism |
| SummonAdditionalLinks | – databaseName: Elsevier SD Freedom Collection dbid: .~1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3di9QwEA_HgeCL-O2eH0TwTeI2adOmvunicXgogh7cW0jaRHps22XbPTgf_LP8-5xJP2RRTxD6siFp2sx05jez80HIC2wZosrUsEIKyUDfxkyVmWEiV8JnUVqUHl0DHz6mJ2fJ-3N5fkBWUy4MhlWOsn-Q6UFajyPL8TSXm6pafhaCx4D20a0ZmuNhBnuSIZe_-s5nPwuYL1yERrI4n-GCMXdmCPO6wGKv2EM81DrlYk8_hTL-e2rqbzA0qKPj2-TWiCPpm-FR75AD19wlN4bOklf3yI-V8735VpVVDe9zWVlT9KZmYFsjXmx6Wjv0wjeuZt2uC6Etdu3o6acV24QasKDR6Ona2a7C8Ci6adwOGLYy7jWd6pjQ1tMClGBHTVPSX2XDcbxq6GXVb1uKeRPYngIHfQsQub6CezOMkB96U1A4ebDOB8fhfXJ2_O7L6oSNLRqAtpnomS9VkRQmTkyae248504AEM5LL3IPxpE1NnJYo9ABzaW0qRKJcl5FLljlefyAHDZt4x4RmsRZkebCSoBEYEVxA0hJWilyLq3IlFsQPhFGF2P9cmyjsdZToNqFRmJqJKaO4OJiQV7OazZD9Y5rZ79Fes8zsfJ2GGi3X_XIehrwkLc897bIigSkoeXwjilcKvIm8umCxBO36Cm5FcQx3Ki6duvsT6tcN0qUTnPdCR3p37h-QeS8cu_D-eeOzydW1iBR8G8i07h212mhIhksTb4gDwcen48kzsAEVjk_-s9dH5Ob-GuItXtCDvvtzj0FVNfbZ-Gz_QmZ60v4 priority: 102 providerName: Elsevier |
| Title | Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae: Analysis of cases and evaluation of in vitro activity of fosfomycin-containing combinations |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2213716523000589 https://www.clinicalkey.es/playcontent/1-s2.0-S2213716523000589 https://dx.doi.org/10.1016/j.jgar.2023.03.012 https://www.ncbi.nlm.nih.gov/pubmed/37086891 https://www.proquest.com/docview/2805025591 https://doaj.org/article/124fb19fbc7c4322b1bab6ab680fa0f6 |
| Volume | 33 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9wwEBVteumltPTLabqo0FtRY8mWP3pLl4Rtl4RCG8hNSLYEDmt7ib2B9pCfld_XGdneJtAml4LZg7Aso3nWvNGO3hDyHkuGZGWiWSGFZOBvI5aVqWYiz4RLw6QoHW4NHJ8ki9P465k8u1HqC3PCBnngYeL2wf84w3NnirSIAX2GG20SuLLQ6dB5sW3weTeCKUCSxFKEiT8NKQQMD0GBHE_MDMld5yjxipXDvcIpF7e8khfvv-Wc_kU-vRM6ekqejOyRHgxv_Yw8sM1zcj23rte_qrKq7b6-rIwuel0ziKORGzY9rS3uuDe2Zt2m82ksZmXp8tucrb3eK3gvulxZ01WYCkXXjd0AOCttP9FJs4S2jhbg8Dqqm5L-kQjH9qqhl1V_0VI8I4GlKLDRtUCH65_wbIbZ8EMdCgrwhkh82CR8QU6PDn_MF2wsxwB2TEXPXJkVcaGjWCe549pxbgWQ3rx0IncQCIFdQot6hBbsKyVYSMSZdVlofQSeRy_JTtM29jWhcZQWSS6MBPoDERPXwIqkkSLn0og0swHhkzlUMWqVY8mMlZqS0s4VmlChCVUIFxcB-bDtsx6UOu68-zNaeXsnqmz7BsCeGrGn7sNeQKIJI2o6yApLLzyounPo9G-9bDeuHp3iqhMqVN8RuwhdCBN9-ceAyG3PkSANxOfeEd9NAFaweuBfQrqx7aZTIoNvBaNKHpBXA7K3UxKlEO5mOd_9H1P1hjzGFxqS7PbITn-xsW-BzvVmRh5-vOIz8ujgy3JxMvPfMfweXx3-BkidTbQ |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBddythexr6XfWqwtyFqyZYt760LK-nShsFa6JuQbGm4JHaInUL3h-3v250_MsK2DgZ-kn2WrTvfl0-_I-QdtgxReWxYJoVkYG9DpvLEMJEq4ZMgznKPqYHTeTw9jz5fyIs9Mhn2wmBZZa_7O53eaut-5KBfzYNVURx8FYKH4O1jWrNtjneL7CM6lRyR_cPj2XS-TbVABMNF20sWSRjS9NtnukqvS8R7xTbiLdwpFzsmqkXy37FUf_NEW4t0dJ_c611Jetg97QOy58qH5HbXXPL6Efkxcb4x34u8WMIrXRXWZI1ZMgiv0WUsG7p0mIgv3ZLVm7qtbrELR2dfJmzVwsCCUaOzhbN1gRVSdFW6DchsYdwHOkCZ0MrTDOxgTU2Z01_I4ThelPSqaNYVxa0T2KECB30FXvLyGu7NsEi-a09BYfEhQO9yh4_J-dGns8mU9V0agL2JaJjPVRZlJoxMnHpuPOdOgC-c5l6kHuIja2zgEKbQAdultLESkXJeBa4NzNPwCRmVVemeERqFSRanwkrwiiCQ4gacJWmlSLm0IlFuTPjAGJ31EObYSWOhh1q1S43M1MhMHcDBxZi839KsOgCPG6_-iPzeXong2-1Atf6me-nT4BJ5y1NvsySLQCFaDu8Yw6ECbwIfj0k4SIse9reCRoYbFTdOnfyJytW9Uqk117XQgf5N8MdEbil3vp1_zvh2EGUNSgX_FJnSVZtaCxXINtjkY_K0k_HtkoQJRMEq5c__c9Y35M707PREnxzPZy_IXTzTld69JKNmvXGvwMlr7Ov-I_4JPr9QNw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ceftazidime%2Favibactam-resistant+meropenem-susceptible+KPC-producing+Klebsiella+pneumoniae%3A+Analysis+of+cases+and+evaluation+of+in+vitro+activity+of+fosfomycin-containing+combinations&rft.jtitle=Journal+of+global+antimicrobial+resistance.&rft.au=Oliva%2C+A&rft.au=Al+Ismail%2C+D&rft.au=Arcari%2C+G&rft.au=Miele%2C+M+C&rft.date=2023-06-01&rft.issn=2213-7173&rft.eissn=2213-7173&rft.volume=33&rft.spage=321&rft_id=info:doi/10.1016%2Fj.jgar.2023.03.012&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2213-7165&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2213-7165&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2213-7165&client=summon |